All Pharma News
USAN Council & INN Expert Committee Recognizes New Therapeutic nibrozetone

USAN Council & INN Expert Committee Recognizes New Therapeutic nibrozetone
PR NEWSWIRE
06 Jul 2023
Share Share
EpicentRx Presents Updates on its Oncology Clinical Development Programs at ASCO

EpicentRx Presents Updates on its Oncology Clinical Development Programs at ASCO
PR NEWSWIRE
02 Jun 2023
Share Share
EpicentRx Receives Fast Track Designation from U.S. FDA for Lead Asset, RRx-001

EpicentRx Receives Fast Track Designation from U.S. FDA for Lead Asset, RRx-001
PR NEWSWIRE
29 Mar 2023
Share Share
Promising Safety and Efficacy Signals from a Small Phase 1 Pilot Study (PRIMETIME) with RRx-001 + Opdivo in Traditionally Checkpoint Inhibitor Non-Responsive Tumors

Promising Safety and Efficacy Signals from a Small Phase 1 Pilot Study (PRIMETIME) with RRx-001 + Opdivo in Traditionally Checkpoint Inhibitor Non-Responsive Tumors
PR NEWSWIRE
15 Mar 2023
Share Share
EpicentRx makes case for cancer toxicity prevention drug

EpicentRx makes case for cancer toxicity prevention drug
Nick Paul Taylor FIERCE BIOTECH
20 Jan 2023
Share Share
EpicentRx to Present for PII Trial to Assess Efficacy of RRx-001 vs. regorafenib

EpicentRx to Present for PII Trial to Assess Efficacy of RRx-001 vs. regorafenib
PR NEWSWIRE
20 Jan 2023
Share Share
EpicentRx Publishes Phase 2 Results for RRx-001 as an Anti-Mucositis Agent

EpicentRx Publishes Phase 2 Results for RRx-001 as an Anti-Mucositis Agent
PR NEWSWIRE
19 Jan 2023
Share Share
RRx-001 + Irinotecan Significantly Improved PFS Versus Regorafenib in PII Trial

RRx-001 + Irinotecan Significantly Improved PFS Versus Regorafenib in PII Trial
PRNEWSWIRE
14 Dec 2022
Share Share
EpicentRx Announces Patent Issued for Radiation Protection with RRx-001

EpicentRx Announces Patent Issued for Radiation Protection with RRx-001
PRNEWSWIRE
06 Dec 2022
Share Share
EpicentRx Awarded Funding from FightMND to Evaluate Potential of RRx-001

EpicentRx Awarded Funding from FightMND to Evaluate Potential of RRx-001
PRNEWSWIRE
29 Nov 2022
Share Share